Martin Schlumberger

7PUBLICATIONS
35CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyEnvironmental biogeochemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 03, 2023
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms.

Tommaso Porcelli, Marialuisa Moccia, Maria Angela De Stefano

|Apr 19, 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.

Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud

|Jun 21, 2022
Post-operative radioactive iodine administration in patients with low-risk thyroid cancer.

Sophie Leboulleux, Isabelle Borget, Martin Schlumberger

|May 07, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.

Lori J Wirth, Marcia S Brose, Eric J Sherman

|Feb 19, 2021
The importance of the RET gene in thyroid cancer and therapeutic implications.

Domenico Salvatore, Massimo Santoro, Martin Schlumberger

|Dec 19, 2020
Current practice in patients with differentiated thyroid cancer.

Martin Schlumberger, Sophie Leboulleux

Pageof 2